Avasimibe Dampens Cholangiocarcinoma Progression by Inhibiting FoxM1-AKR1C1 Signaling.

Gao, Yunshu; Xu, Dongyun; Li, Hongwei; Xu, Jiahua; Pan, Yating; Liao, Xinyi; Qian, Jianxin; Hu, Yi; Yu, Guanzhen

Gao, Yunshu; Xu, Dongyun; Li, Hongwei; Xu, Jiahua; Pan, Yating; Liao, Xinyi; Qian, Jianxin; Hu, Yi; Yu, Guanzhen.

Afiliação

Gao Y; Department of Oncology, People's Liberation Army General Hospital, Beijing, China.
Xu D; Department of Oncology, The 71st Group Army Hospital of People's Liberation Army, The Affiliated Huaihai Hospital of Xuzhou Medical University, Xuzhou, China.
Li H; Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xu J; Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Pan Y; Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Liao X; Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Qian J; Department of Oncology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Hu Y; Department of Oncology, People's Liberation Army General Hospital, Beijing, China.
Yu G; Precision Medical Center laboratory, The First Affiliated Hospital of Wenzhou Medical University, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

Front Oncol ; 11: 677678, 2021.

Article em En | MEDLINE | ID: mdl-34127944

Palavras-chave

AKR1C1; FoxM1; avasimibe; cholangiocarcinoma; progression

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google